Nicolau Syndrome: A Review of Case Studies

Paria Mojarrad1, Hamid Mollazadeh1,2, Behnaz Barikbin1, Mohammad Bagher Oghazian1,4*

1Clinical Research Development Unit, Imam Hasan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran.
2Department of Physiology and Pharmacology, North Khorasan University of Medical Sciences, Bojnurd, Iran.
3Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
4Department of Internal Medicine, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.

Abstract
Nicolau syndrome, although it is quite rare, often occurs following intramuscular injections of different medications, especially diclofenac and penicillins. Accordingly, its symptoms usually begin with severe pain during injection, leading to ulceration and necrosis of the local tissue over time. Immediate diagnosis and treatment in the case of this syndrome, are of great importance. There are no established criteria for Nicolau's diagnosis, and preferably, these can be achieved by examining the patient's symptoms and eliminating differential diagnoses. The proposed treatments are primarily symptomatic therapy and measures such as fasciotomy, debridement, and plastic surgery provided in the affected area. The exact cause of this syndrome has not been determined yet. However, since vasospasm, thrombosis, and embolism have been observed in most of Nicolau syndrome cases, so any intra-arterial/para-arterial injection or any other factor leading to these three conditions could be hypothetically regarded as the cause of this problem. This review aims to provide a comprehensive overview of Nicolau's symptoms, diagnosis, treatment methods, and prevention. It also investigates the association between the incidence of this disease and some factors such as gender, age, injection method, and causative drugs, in order to widen our understanding on this syndrome and help practitioners with a much faster diagnosis method and step-by-step approach to Nicolau syndrome.

Introduction
Nicolau syndrome is a sporadic, iatrogenic syndrome, which was firstly reported by Freudenthal and Nicolau in 1924 and 1925, respectively, following the intramuscular injections of bismuth to treat syphilis. This syndrome is also known as Embolia Cutis Medicamentosa (ECM) and Livedo-Like Dermatitis (LLD). In addition, the syndrome often occurs as a sudden and severe local pain following skin reaction and neurovascular phenomenon in the injection site, to which it is usually confined. This syndrome in most cases has taken place after intramuscular injection of the following drugs: penicillin, non-steroidal anti-inflammatory drugs (NSAIDs), topical anesthetics (lidocaine), vaccines, corticosteroids, vitamin K, antihistamines, polidocanol, and pegylated interferon-alpha.1,2 Although this syndrome has been found to be usually associated with intramuscular injection, several researchers in their studies have related it to subcutaneous, intravenous, and intra-articular injections of some drugs.3,6 The reason for this complication has not been established yet; however, intra/periarterial injections and their consequent complications such as ischemia and spasms are known as the possible contributing factors.7 It was indicated that injecting cytotoxic drugs can also lead to perivascular inflammation and ischemic necrosis.7 A lipophilic drug can penetrate and block the vessels, resulting in fat embolism. As well, Sweat gland necrosis has been reported in some studies on Nicolau syndrome.8-10 Management and treatment strategies proposed for this disease vary from one case to another, which usually are supportive and symptomatic.11 The consequences of Nicolau syndrome convince the practitioners to implement many precautions like syringe aspiration before injection, in order to ensure no intravascular infusion, use of the Z-track technique, the accurate preparation of the injection site, prevention of high dose injections in one site, and regularly changing the injection site in case of multiple injections.12

This study aimed to search the literature and review all clinical aspects of Nicolau syndrome, i.e., symptoms, etiology, diagnosis, treatment methods, and prevention with all offending agents causing this syndrome.

Overview of Case Studies
Data collection
The search was conducted for English articles published up to April 1, 2021, in some electronic databases, including...
PubMed, Medline, Scopus, Web of Science, and Google Scholar, using the heading terms Nicolau syndrome, OR Embolia Cutis Medicamentosa (ECM), OR Livedo-Like Dermatitis (LLD). Thereafter, demographic data, clinical characteristics, offending agent(s), route of administration, symptoms, and type of treatments were assessed in the included articles.

Findings
Some articles did not mention a number of details such as length of hospitalization, injection method, and gender. In total, 150 cases obtained from different databases were reviewed, and the final analysis was only performed based on the available articles, the results of which were mentioned.

Analysis
Demographic characteristics
Analysis of those articles that had taken patients’ gender into account (133 cases) indicated that the incidence of Nicolau syndrome is higher in women (n= 83; 62.40%). As well, the patients’ age had been addressed in 135 cases, as shown in Table 1. Evaluating different age groups showed that the highest incidence rate of Nicolau syndrome is among adults aged between 30 and 40 years old and children aged up to 10 years old with 20% and 19.26%, respectively.

Route of administration
Examining the articles that referred to the injection route as the leading cause of Nicolau syndrome (105 articles), indicated that this complication occurs more frequently with intramuscular injection (83 articles, 79.05%). Moreover, other administration methods that gave rise to Nicolau syndrome were subcutaneous injection (12 articles, 11.43%) and intra-arterial injection (4 articles, 3.81%). Notably, intravenous injection, intradermal injection, and intra-articular injection all share the same proportion of 1.90% (2 articles each).

Medication inducing Nicolau syndrome
Reviewing those articles dealing with drugs (145 articles) revealed that the most common causes of the syndrome are diclofenac (35 articles, 24.14%) and penicillins (32 articles, 22.07%). Table 2 presents the incidence of Nicolau syndrome reported by the reviewed articles.

Symptoms
In general, the onset of Nicolau syndrome in about 90% of the affected cases was accompanied with severe pain during injection. After several hours, this was followed by livedoid, discoloration of the affected area, and ulceration in the injection site. After several days, about 55% of the cases developed necrosis in the affected area and necessitated debridement.

In most cases, post-injection symptoms (including tissue discoloration, livedoid, ulcer, and necrosis) were confined to the injection site. In contrast, in approximately 25% of the cases, these were observed in other organs such as hands, thighs, feet, and fingers. Of note, more than half of these cases were children. Subsequently, Blood tests and vital signs were examined, which were relatively standard in most cases, but neutrophils and leukocytes, alanine transaminase (ALT) and aspartate transaminase (AST), and lactate dehydrogenase and creatine kinase increased in few cases. Given that Nicolau syndrome has different phases, it can occasionally be hazardous, and entail irreparable consequences, and even can cause death. About 4.5% of the reported cases had ended in mortality.

Treatment
The most frequent treatments performed in the reviewed cases were pharmacotherapy and debridement of necrotic tissue (Table 3).

As well, Pharmacotherapy was mainly applied through systemic antibiotics, anticoagulants, systemic corticosteroids, blood viscosity reducers, antibiotics, topical corticosteroids, and various analgesics, including NSAIDs and opioids. Generally, in most of the reviewed studies, therapy was started by symptomatic treatment of pain, bruising, swelling, and inflammation of the injection site. In symptoms exacerbation or necrotic lesions (reported in approximately 55% of the included studies), some measures such as fasciotomy, necrotic tissue debridement, and plastic surgery (even amputation in case of extensive necrosis) were adopted. Accordingly, fasciotomy was performed often successfully in most cases, when the blood flow to the injection site or its surrounding area could not be detected or when it had been interrupted. Depending on the severity of the tissue damage and the speed, the patients were provided with a correct diagnosis and appropriate treatment. In this regard, the treatment courses mostly ranged from one to two months. However, these occasionally lasted from one week to nine months.

Discussion
Symptoms
Symptoms of Nicolau syndrome vary depending on its three phases. The primary symptoms could be dermatological, neurological, and cardiovascular signs.

Table 1. age distribution of 135 cases addressed in the final articles.

| Age group (years old) | Number of cases out of 135 | Percentage |
|-----------------------|---------------------------|------------|
| 0-10                  | 26                        | 19.26%     |
| 10-20                 | 11                        | 8.15%      |
| 20-30                 | 15                        | 11.11%     |
| 30-40                 | 27                        | 20%        |
| 40-50                 | 15                        | 11.11%     |
| 50-60                 | 14                        | 10.37%     |
| 60-70                 | 14                        | 10.37%     |
| 70-80                 | 12                        | 8.89%      |
| 80-90                 | 1                         | 0.74%      |
A Review of Nicolau Syndrome

**Table 2.** The incidence of Nicolau syndrome associated with different drugs.

| Offending agents | Number of cases out of 145 cases | Percentage | Reference |
|------------------|----------------------------------|------------|-----------|
| Diclofenac       | 35                               | 24.14%     | 1,7,8,12-37 |
| Penicillin derivatives | 32                      | 22.07%     | 11,13,17,38-56 |
| Glatiramer acetate | 7                                  | 4.82%      | 57,58     |
| Hyaluronic acid  | 6                                 | 4.14%      | 1,30,50-63 |
| DTP (Diphtheria-Tetanus-Pertussis) | 4                        | 2.76%      | 66-68     |
| Bismuth salicylate | 3                                  | 2.07%      |           |
| Lidocaine        | 3                                 | 2.07%      | 8,17,69,70 |
| Piroxicam        | 3                                 | 2.07%      |           |
| Dexamethasone    | 2                                 | 1.38%      |           |
| Ibuprofen        | 2                                 | 1.38%      |           |
| Interferon alpha | 2                                 | 1.38%      |           |
| Oxytocin         | 2                                 | 1.38%      | 5,18,70-78 |
| Polidocanol      | 2                                 | 1.38%      |           |
| Thiocolchicoside | 2                                 | 1.38%      |           |
| Triamcinolone acetoniode | 2                         | 1.38%      |           |

Acetaminophen (Paracetamol), Anti-flu vaccine, B complex vitamin, Bortezomib, Buprenorphine, Calcium hydroxide, Ceftriaxone, Chlorpheniramine maleate, Chlorpromazine, Cortizol, Cyanocobalamin (Vitamin B12), Cyclicine, Dicyclomine, Diphenhydramine, Epinephrine, Etanercept, Etofenamate, Gentamicin, Hydrocortisone, Hydroxyzine, Interferon Beta, Ketoprofen, Ketorolac, Meperidine, Methylprednisolone, Naltrexone, Paramethasone, Phenobarbital, Phenylbutazone, Pneumococcal vaccine, Sodium tetradecyl sulfate, Streptomycin, Sulpyridine, Sulfonamide, Terlipressin, Tetracycline, Varicella vaccine, Vitamin K

*The frequency of each one of these drugs is one case.

alone or simultaneously. Severe pain and discoloration of the injection site occurring immediately after injection, livedo reticularis (net-like purplish discoloration), and hemorrhagic lesion are known as usual symptoms of this complication. In addition to these symptoms, which mainly occur on the skin's surface, secondary problems such as necrosis, infection, and scarring may also be presented in muscle tissue and subcutaneous fat.

**Table 3.** Frequency of the therapeutic measures implemented for Nicolau syndrome.

| Intervention                                         | Percentage |
|------------------------------------------------------|------------|
| Debridement                                          | 12%        |
| Plastic surgery and skin graft                       | 5%         |
| Fasciotomy                                           | 4%         |
| Amputation                                            | 2%         |
| Hemodialysis                                         | 0.5%       |
| Pharmacotherapy                                       | 76.5%      |
| Systemic Antibiotic therapy (Amikacin- Aminocillin- Aztreonam- Cefazolin- Cefotaxime- Ceftriaxone- Cephalixin-Ciprofloxacin- Clindamycin- Gentamycin- Imipenem- Linezolid- Meropenem- Metronidazole- Piperacillin- Tazobactam- Ticarcillin) | 16.5%      |
| Anti-coagulants (Enoxaparin - Heparin)                | 11.5%      |
| Systemic corticosteroid                              | 9%         |
| Blood viscosity reducer agent (Pentoxifylline)       | 6.5%       |
| Topical antibiotic (Mupirocin)                       | 6%         |
| NSAIDs                                               | 5%         |
| Antiplaetelet (Aspirin- Clopidogrel- Dipyridamole)   | 3.5%       |
| Topical corticosteroids                              | 3.5%       |
| Opioid analogics (Morphine- Pethidine)               | 2.5%       |
| CCB (Amlopidine- Diltiazem- Nifedipine)              | 2.5%       |
| Vasodilator (Alprostadil- Nitroglycerin transdermal) | 2.5%       |
| Hyperbaric Oxygen therapy (HBOT)                     | 2.5%       |
| Hyaluronic acid                                      | 1.5%       |
| Pregabalin                                           | 1%         |
| Post therapeutic neurology (Amitriptyline- Gabapentin) | 1%         |
| Probenecid                                          | 0.5%       |
| Epinephrine                                         | 0.5%       |
| Albuterol                                            | 0.5%       |

Pharmaceutical Sciences, 2022, 28(1), 27-38 | 29
Neurological signs are the vast proportion of the symptoms that could lead to unilateral or bilateral sensory and motor disorders.\textsuperscript{38,70} Accordingly, these seem to occur due to axonopathy, secondary to vascular problems such as embolism and vascular occlusions. Moreover, these are ranged from burning and numbness, starting from the initial phase, to dystonia, paresthesia, paraplegia, and sensitivity. Due to axonopathy and injury in one or more nerves at the injection site, symptoms can occasionally spread to other organs, such as the shoulder, thigh, knee, and ankle.\textsuperscript{14,56} Additionally, dizziness, fainting, loss of consciousness or cognitive changes have been reported in some cases.\textsuperscript{56,99,100} As well, it was observed that some normal functions could be disrupted due to the location and extent of the damaged nerve, which can consequently lead to nausea, vomiting, loss of bladder or bowel control, renal failure, and even death.\textsuperscript{40,56,61}

Dermatological manifestations usually appear from the beginning of the initial phase. Correspondingly, these contain paleness, erythema, and livedoid violaceous patch at the injection site, as well as a hemorrhagic lesion, contributing to cutaneous necrosis.\textsuperscript{7,27}

In terms of cardiovascular signs, the coldness of the injection site and the absence of pulses in the area have been observed in some cases.\textsuperscript{38,43,44}

Table 4 summarizes all the symptoms of three phases of Nicolau syndrome and the treatments used for the studied patients.

**Table 4. Clinical symptoms in different phases of Nicolau syndrome and their respective treatments.**

| Phase     | Symptoms                                      | Probability | Approximate treatment (most used)                                      | Usual duration |
|-----------|-----------------------------------------------|-------------|-----------------------------------------------------------------------|----------------|
| Initial   | Intense pain                                  | Common      | Analgesics, Rest, Warm compress, Avoid cold compress, Hyperbaric oxygen | 1-3 days       |
|           | Paleness of injection site                    | Uncommon    |                                                                        |                |
|           | Paresthesia                                   | Uncommon    |                                                                        |                |
|           | Bluish discoloration                           | Common      |                                                                        |                |
|           | Erythema                                       | Common      |                                                                        |                |
|           | Livedo-like dermatitis                         | Common      |                                                                        |                |
|           | Maybe syncope (fainting)                      | Rare        |                                                                        |                |
|           | Tenderness on the site of injection            |             |                                                                        |                |
|           | Hemorrhagic Lesion                             |             |                                                                        |                |
|           | Swelling                                       |             |                                                                        |                |
|           | Fever                                          |             |                                                                        |                |
|           | Spasm and coldness and mottling of the limb   | Uncommon    | NSAIDs, Acetaminophen                                                  |                |
| Acute     | Discoloration and purplish livedoid in the injection site | Uncommon | Vasoactive compress                                                    | 5-10 days      |
|           | Erythematous lesion. Livedoid violaceous plaque | Common      | Antibiotics, Vasoactive agents, Anticoagulants                         |                |
|           | Urosepsis and soft tissue infection            | Rare        | Antibiotics                                                           |                |
|           | Vomiting                                       | Rare        | Antiemetic                                                            |                |
|           | Absence of pulses                              | Uncommon    | Fasciotomy                                                            |                |
| Necrotic  | Necrotic, crusted, and indurated plaque        | Uncommon    | Debridement, Skin graft, Corticosteroids IV/Topical                    | 5 days- 2 weeks|
|           | Injection site or limb necrosis               | Uncommon    |                                                                        |                |

**Etiology**

The etiology of this syndrome is not well-known yet, so microscopic and biopsy studies suggesting ischemic tissue necrosis have put forth several hypotheses that could mainly be classified into the following three theories: inadvertent intra/peri-arterial injection, leading to embolism and vascular occlusion; vasospasm due to the needle prick of the injected drug; and applying a cold compress to the lesion site.\textsuperscript{101} There is evidence demonstrating primary or secondary vascular thrombosis of the reticular dermis with no vasculitis.\textsuperscript{13} In addition, no convincing evidence exists to explain the mechanisms of inflammation and cell damage in Nicolau syndrome. In all the examined cases, microbial culture was reported as negative; therefore, sterility non-compliance has been generally eliminated from the list of the possible causes in this regard.

Histological studies conducted in most cases suggest that microemboli obstruction in skin arteries and tissues can be considered as a significant concept during the development of syndrome. Moreover, neurologic disorders of the extremities and lower limb paralysis can be justified by a drug embolism.\textsuperscript{102} Accordingly, this is a fact that no vasculitis or malignancy exists in the affected area’s tissue.\textsuperscript{12}

Saputo and Bruni reported the majority of Nicolau syndrome cases in children under the age of five years old. They attributed it to the smaller size of vessels and the higher probability rate of arterial embolism in this age group.\textsuperscript{103} Conversely, Senel et al.\textsuperscript{14} noted the higher incidence of this syndrome among adults. As well, another possible cause of the embolism occurring following benzathine
A Review of Nicolau Syndrome

penicillin G injection, including condensed, viscose, and opaque suspensions, can hinder aspirated blood from being detected in the syringe. As a result, aspiration is not performed accurately or the clots might subsequently result in microemboli. In case of any inadvertent intra-arterial injection, this can persist in the narrowed arteries of the lower extremities and skin of the affected area and then trigger embolism.\textsuperscript{11,39,40} In an animal study performed by Brachtel et al.\textsuperscript{10,14}, it was reported that both para-arterial and intra-arterial injections of phenylbutazone to rabbit ears led to severe inflammation and necrosis in the affected area and caused severe damage to the inner arterial wall. The results of this study partially support the theory mentioned above, stating that the leading cause of Nicolau syndrome is a pre-arterial or intra-arterial injection.

It is most probable that a combination consisting of vasospasm, thrombosis, and embolism mechanisms is involved in developing the final lesion. In this regard, Embolism and thrombosis have been previously reported to occur following the inadvertent intravenous injection. Vasospasm can be resulted from many factors (including compression of the artery, direct vascular injury by the needle prick or localized immune-allergic reaction), which leads to necrosis. Drug molecules can be identified as haptons and then trigger the body's immune responses, followed by thrombosis leading to necrosis.\textsuperscript{105} Blood tests of most Nicolau syndrome cases have revealed no cellulitis, and they were normal.\textsuperscript{17,15} Meanwhile, it was indicated that several cell-damaging factors such as lactate dehydrogenase, creatine kinase, and myoglobin have intensified in some patients with Nicolau syndrome.\textsuperscript{20,38,49,53}

Diagnosis

There is no confirmatory test for Nicolau syndrome; therefore, its diagnosis is often performed based on patients' medication history and clinical symptoms. So, it is crucial to be familiar with the usual symptoms of Nicolau syndrome and consider it a possible occurrence. Every person with severe injection-site pain immediately after injection could be subjected to this complication. In this regard, no deterministic criteria are available for identifying this syndrome, and its diagnosis is solely performed based on clinical symptoms following a recent injection and after ruling out the possibility of similar disorders.\textsuperscript{8,13,15,16,99,106} Necrotizing fasciitis is the most important differential diagnosis used for Nicolau syndrome.\textsuperscript{3} Moreover, other differential diagnoses of this syndrome are the following: local toxic reaction to drugs, acute compartment syndrome, vasculitis, fat embolism, and Hoigne's syndrome.\textsuperscript{56} Injection nerve injury diagnosis, which could lead to nerve palsy, is known as another differential that puts unqualified staff injecting into an inappropriate site. Although Nicolau syndrome almost presents dermatological symptoms, usually there are no dermatological symptoms caused by the injection nerve injury.\textsuperscript{56,107,108} Cellulitis is another differential diagnosis whose misdiagnosis could consequently lead to antibiotics administration and treatment failure.\textsuperscript{109} Gas gangrene and necrotizing fasciitis are acute infections considered as other differential diagnoses for Nicolau syndrome. Correspondingly, these could quickly spread and then contribute to necrotic damage of muscle, and their symptoms are easily mistaken for Nicolau syndrome. Skin culture and imaging are essential tools to cross gas gangrene out.\textsuperscript{110-112} Ruling all differential diagnoses out from the list is possible by asking for a complete medical history from the patient, taking a blood test, local microbial culture, and conducting pathological examinations.

Treatment

No standard treatment has been proposed for Nicola syndrome so far. Depending on the disease's phase and its symptoms, its healing procedures range from supportive local or systemic treatment for pain, swelling, erythematous lesion to surgical interventions like debridement of the necrotic tissue. Besides these symptomatic treatments, some studies have previously suggested the use of anticoagulants, antiplatelets, blood viscosity reducer agents, vasodilators, and topical or oral corticosteroids to treat this syndrome.\textsuperscript{95-98,113}

Some other studies have recommended hyperbaric oxygen for treating this complication. The use of cold compresses is also known to exacerbate Nicolau syndrome. In this regard, appropriate antibiotic regimens may be prescribed, usually in the second or third phase of the syndrome, for those cases in whom the lesion is infected.\textsuperscript{14,50} In more than half of cases with this syndrome, necrosis and secondary infection of the skin and underlying muscles could be detected, and under this condition, debridement of the necrotic tissue improves the patient's status.\textsuperscript{35,99} In addition, in those cases with the absence of pulses, fasciotomy produced favorable outcomes.\textsuperscript{41,46}

Clinical improvement of symptoms in different phases of the disease, including initial, acute, and necrotic, has occurred after resting the injured limb and administering appropriate symptomatic and etiological therapies. Prevention of inflammation, vasodilation, improvement of blood flow, the increased blood dilution, and preventing the dissemination of infection and its treatment are included among these therapeutic agents' effects. Although the therapeutic effectiveness of the above-mentioned medications and approaches has not been widely confirmed yet, some of these treatments that were applied experimentally have yielded several positive outcomes (Table 4). The characteristics of all Iranian cases with Nicolau syndrome have been provided in the appendix.

Prevention

Several interventions can be utilized to prevent or minimize the side effects of Nicolau syndrome. First and foremost, choosing an appropriate site of injection is critical in this regard. For example, intramuscular injection in the buttock must be administered in the right site located in the upper-outter quadrant to minimize Nicolau syndrome's risk and
prevent the injection nerve injury, which could contribute into injection palsy.\textsuperscript{114} Additionally, another solution is choosing correct injection techniques such as Z-track and proper needle length appropriate for the site of injection, type of injection, and patient's weight. Accordingly, for a patient weighing 90 kg, the best needle is a 2-inch one and a 1.25 to 1.45 inches needle is appropriate for a person weighing 45 kg.\textsuperscript{12} This is especially vital in overweight or obese people with high-fat mass in the injection site (e.g., around their abdomen and buttocks) to ensure that the injection is intramuscular. In vials containing the suspension, one must also ensure uniformity of the suspension and its lack of clots. Furthermore, injection must be stopped in case of severe burning pain reported by patients.\textsuperscript{11,115}

To ensure that the vessels are not damaged, aspiration should be performed before any injection. Besides, intramuscular injection must never be performed more than 5 mL in one site. Finally, the rotation should be maintained if multiple injections are required at once (Table 5).\textsuperscript{12,21,96,115}

| The effective way to prevent | Explanation(s) |
|-----------------------------|----------------|
| Ensuring drug’s safety       | Checking expiration date, and using an appropriate solvent |
| Ensuring proper drug’s preparation | Preparing entirely uniformed and clot-free suspension |
| Choosing the right size needle | Ensuring that the needle is long enough to prevent the injection into adipose tissue, but to reach the muscle, especially in the buttock area |
| Selecting the correct injection site | As in the upper-outer quadrant |
| Ensuring the precise amount of injection | Maximum 5 mL in each injection site |
| Ensuring the usage of the correct injection techniques | Syringe aspiration before injection Rotation of injection site if multiple injections are required at once Using the Z-track technique |

**Conclusion**

**Etiology and prevention**

It is mainly argued that intra/peri-arterial injection, contributing to vascular thrombosis, with no vasculitis, or arterial embolism, and vascular occlusion are the primary causes of Nicolau syndrome. As well, needle prick leading to vasospasm is known as another reason. So, Nicolau syndrome is considered as an avoidable complication according to its etiology. Therefore, in order to prevent this syndrome, we can take some actions as follows: 1-Choosing syringe with standard needle size, 2-Ensuring intramuscular injection, 3-Aspiration and using Z-Track technique, 4-Providing an entirely uniform suspension, 5-Choosing the right site for injection 6-Considering Diclofenac and Penicillin as the two main reasons for this syndrome, and 7-Limiting injection volume up to 5 mL in each injection site. Accordingly, adherence to these recommendations is even more critical in individuals with a high body mass index (BMI).

**Diagnosis**

Based on the fact that there is no confirmatory test proposed for Nicolau syndrome diagnosis, paying attention to the history of injection as well as chief complaints of intense pain immediately after injection and other common symptoms such as livedoid dermatitis or hemorrhagic patch is essential. Therefore, by considering no history of pressure, acute compartment syndrome could be ruled out. As well, asking the patient's complete medical history is known as the best approach to omit allergic reactions. Moreover, performing some laboratory tests and pathological examinations are essential to rule out other differential diagnoses. In this regard, it was demonstrated that the pathological examination of local arteries is prone to depict thrombosis or embolism relevant to Nicolau syndrome, so vasculitis and fat embolism could be crossed out by conducting this pathological examination.

On the other hand, if neurological examinations and some tests show local nerve damage, it could be regarded as an injection nerve injury because of the injection performed by unqualified staff and an inappropriate injection site, which leads to nerve palsy. Usually, it is not followed by any dermatological symptom. Furthermore, the negative microbial culture of skin and subcutaneous tissues could reject necrotizing fasciitis, Hoigne’s syndrome, and gas gangrene. Accordingly, for the latter, the use of imaging can lead to a better diagnosis and avoid misdiagnosis.

**Symptoms and treatments**

Eternal duration usually lasts from one week to nine months. Neurological, dermatological, and cardiovascular symptoms presented in this syndrome are common, which can be unilateral or bilateral that spread to limbs and other near organs. These symptoms are categorized into 3 phases based on the time of their occurrence.

The initial phase (the first phase) starts immediately after injection and lasts for 1 to 3 days. At this stage, intense pain at the injection site and paresthesia, neurological symptoms, and paleness gradually lead to bluish discoloration, and livedo-like dermatitis is known as a common symptom. In some patients with this disease, syncope has been observed. The treatments range from rest and warm compress to pharmacotherapy using analgesics and hyperbaric oxygen therapies.

The acute phase (the second phase) starts after the initial phase, which usually lasts for 5 to 10 days. At this stage,
A Review of Nicolau Syndrome

rigidity, tenderness, and swelling of the injection site become obvious. In addition, Erythematous, hemorrhagic lesions, and livedoid violaceous plaque, usually contribute into soft tissue infection and fever. In few cases, urinary tract infections occur, which might eventually lead to urosepsis. As well, the absence of pulses sometimes happens, and following that spasm, coldness, and mottling of the limb appear. Vomiting has also been reported by few cases. Based on the symptoms, the treatment of this disease is categorized into etiological treatment and symptomatic therapy. Since the most probable etiologies for Nicolau syndrome are vascular thrombosis and arterial embolism, so its etiological therapy consists of corticosteroid, antiplatelet, anticoagulant, blood viscosity reducer agent, and vasodilator. Notably, corticosteroids could lower the blockage of arteries by reducing inflammation and swelling of adjacent tissues. Analgesics, antibiotics, antiemetics, and some surgical procedures like fasciotomy, are also included among symptomatic therapies.

The necrotic phase (the third phase) usually lasts for 5 to 14 days. In most cases, hemorrhagic lesion subsequently leads to the construction of indurated, crusted, and necrotic plaque of the skin and subcutaneous tissues. Sometimes the plaque becomes infected and rarely contributes to mortality. In this phase, debridement and antibiotic therapy are the main treatments, followed by plastic surgery and pharmacotherapy that can be performed for pain and inflammation if necessary.

Figure 1 illustrates the stages of Nicolau syndrome after involving the predisposing factors in the injection, i.e., initial, acute, and necrotic phases. The treatment approaches consist of pharmacotherapy and surgery. In the latter, the possible outcomes are healing, amputation, and death.

Suggestions
Since Nicolau syndrome is still a rare severe complication with no specific test to diagnose, the certainty of its correct diagnosis should be the first and foremost priority for physicians. In most cases, corticosteroids are prescribed from the second phase of this disease, which might be why most of them end up necrosis. Performing the etiological treatments like corticosteroids immediately after diagnosis and from the start of the first phase could be advisable to decrease both the duration and intensity of the symptoms and to prohibit or lower the risk of tissue necrosis. It is vital to consider that using corticosteroids can drastically exacerbate infections.

In conclusion, immediate diagnosis of Nicolau syndrome, implementing supportive and therapeutic measures as soon as possible, and administering appropriate adjunct medications are among the most critical components for preventing and treating this complication.

Ethical Issues
The photos used in Figure 1 were selected from a collection of photos taken from our patient with Nicolau syndrome, with their informed consent.

Author Contributions
PM: Methodology, Formal analysis, Investigation, Data curation, Writing - Original draft preparation, and Visualization. HM: Validation, Writing - Reviewing and Editing, and Visualization. BB: Validation, Resources, and Writing - Reviewing and Editing. MBO: Conceptualization, Validation, Writing - Reviewing and Editing, Supervision, and Project administration. All authors read and approved the final manuscript.

Conflict of Interest
The authors report no conflicts of interest.
References

1. Nischal K, Basavaraj H, Swaroop M, Agrawal D, Sathyaranayana B, Umashankar N. Nicolau syndrome: An iatrogenic cutaneous necrosis. J Cutan Aesthet Surg. 2009;2(2):92-5. doi:10.4103/0977-2077.58523
2. Senel E. Nicolau syndrome: A review of the literature. Clin Med Insights Dermatol. 2010;3:1-4. doi:10.4137/CMID.S3630
3. Geukens J, Rabe E, Bieber T. Embolia cutis medicamentosa of the foot after sclerotherapy. Eur J Dermatol. 1999;9(2):132-3.
4. Cherasse A, Kahn MM, istrih R, Maillard H, Strauss J, Tavernier C. Nicolau's syndrome after local glucocorticoid injection. Joint Bone Spine. 2003;70(5):390-2. doi:10.1016/s1297-319x(03)00137-4
5. Sonntag M, Hodzic-Avdagic N, Bruch-Gerharz D, Neumann NJ. [Embolia cutis medicamentosa after subcutaneous injection of pegylated interferon-alpha]. Hautarzt. 2005;56(10):968-9. doi:10.1007/s00105-005-0062-6
6. Harde V, Schwarz T. Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate. J Dtsch Dermatol Ges. 2007;5(12):1122-3. doi:10.1111/j.1610-0387.2007.06391.x
7. Kilic I, Kaya F, Ozdemir AT, Demirel T, Celik I. Nicolau syndrome due to diclofenac sodium (voltaren(r)) injection: A case report. J Med Case Rep. 2014;8:404. doi:10.1186/1752-1947-8-404
8. Corazza M, Capozi O, Virgilit A. Five cases of livedo-like dermatitis (nicolau's syndrome) due to bismuth salts and various other non-steroidal anti-inflammatory drugs. J Eur Acad Dermatol Venereol. 2001;15(6):585-8. doi:10.1046/j.1468-3083.2001.00320.x
9. Faucher L, Marcoux D. What syndrome is this? Nicolau syndrome. Pediatr Dermatol. 1995;12(2):187-90. doi:10.1111/j.1525-1470.1995.tb00151.x
10. Ruffieux P, Salomon D, Saurat JH. Livedo-like dermatitis (nicolau's syndrome): A review of three cases. Dermatology. 1996;193(4):368-71. doi:10.1159/000246298
11. De Sousa R, Dang A, Rataboli PV. Nicolau syndrome following intramuscular benzathine penicillin. J Postgrad Med. 2008;54(4):332-4. doi:10.4103/0022-3859.43523
12. Lie C, Leung F, Chow SP. Nicolau syndrome following intramuscular diclofenac administration: A case report. J Orthop Surg (Hong Kong). 2006;14(1):104-7. doi:10.11177/230949900601400123
13. Luton K, Garcia C, Poletti E, Koester G. Nicolau syndrome: Three cases and review. Int J Dermatol. 2006;45(11):1326-8. doi:10.1111/j.1365-4632.2006.02674.x
14. Senel E, Ada S, Güleç AT, Çağlar B. Nicolau syndrome aggravated by cold application after i.m. Diclofenac. J Dermatol. 2008;35(1):18-20. doi:10.1111/j.1346-8138.2007.00404.x
15. Ezzedine K, Vadoud-Seyedi J, Heenen M. Nicolau syndrome following diclofenac administration. Br J Dermatol. 2004;150(2):385-7. doi:10.1111/j.1365-2133.2004.05808.x
16. Okan G, Canter HI. Nicolau syndrome and perforator vessels: A new viewpoint for an old problem. Cutan Ocul Toxicol. 2010;29(1):70-2. doi:10.3109/15656929093496753
17. Marcus F, Claude EV, Josephine M, Teyang A. An exceptional cause of acute limb ischemia: Nicolau syndrome-single-center experience with 4 cases. Ann Vasc Surg. 2019;58:383-383. E11. doi:10.1016/j.avsg.2018.11.022
18. Adil M, Amin SS, Arif T. Nicolau's syndrome: A rare but preventable iatrogenic disease. Acta Dermatovenerol Croat. 2017;25(3):251-3.
19. Gulseren D, Sahin EB, Bozdogan O, Artuz F. An avoidable adverse drug reaction: Nicolau syndrome. Int Wound J. 2017;14(2):440-1. doi:10.1111/iwj.12663
20. Hamilton B, Fowler P, Galloway H, Popovic N. Nicolau syndrome in an athlete following intramuscular diclofenac injection. Acta Orthop Belg. 2008;74(6):860-4.
21. Stricker BH, van Kasteren BJ. Diclofenac-induced isolated myonecrosis and the Nicolau syndrome. Ann Intern Med. 1992;117(12):1058. doi:10.7326/0003-4819-117-12-1058.1
22. Arslan MN, Melez DO, Akcay A, Gur A, Sam B, Guven Apaydin S. Coincidence of nicolau syndrome and rhabdomyolysis: Report of a forensic autopsy case and review of the literature. J Forensic Sci. 2016;61(5):1369-74. doi:10.1111/1556-4029.13126
23. Kocman EA, Yasar FN, Kose AA, Cil Y, Karabagli Y, Cetin C. Freestyle perforator-based fasciocutaneous flap reconstruction in nicolau syndrome-related tissue necrosis. Indian J Surg. 2013;75(3):1189-1193. doi:10.1007/s12262-013-1239-2
24. Kim TH, Lee HH, Kim JM. Bilateral nicolau syndrome after uterine artery embolization for postpartum bleeding. Acta Obstet Gynecol Scand. 2014;93(9):954-5. doi:10.1111/aogs.12396
25. Nayci S, Gurel MS. Nicolau syndrome following intramuscular diclofenac injection. Indian Dermatol Online J. 2013;4(2):152-3. doi:10.4103/2229-5178.110642
26. Kim SK, Kim TH, Lee KC. Nicolau syndrome after intramuscular injection: 3 cases. Arch Plast Surg. 2012;39(3):249-52. doi:10.5999/aps.2012.39.3.249
27. Kim KK. Nicolau syndrome in patient following diclofenac administration: A case report. Ann Dermatol. 2011;23(4):501-3. doi:10.5021/ad.2011.23.4.501
28. Park HJ, Kim MS, Park NH, Jung SW, Park SJ, Park CS. Sonographic findings in nicolau syndrome following intramuscular diclofenac injection: A case report. J Clin Ultrasound. 2011;39(2):111-3. doi:10.1002/
A Review of Nicolau Syndrome

Enshaei A, Afshar A. Compartment syndrome of the calf due to Nicolau syndrome. Arch Bone Jt Surg. 2016;4(1):87-9.

44. Hatefi M, Pirabadi NR, Khajavikhan J, Jaafarpour M. Claudication due to sciatic nerve palsy following Nicolau syndrome: A case report. J Clin Diagn Res. 2015;9(10):RD01-2. doi:10.7860/JCDR/2015/14833.6596

45. Lopes L, Filipe P, Alves A, Guerreiro F, Pires S. Nicolau syndrome after benzathine penicillin treated with hyperbaric oxygen therapy. Int J Dermatol. 2015;54(4):e103-6. doi:10.1111/ijd.12751

46. Noaparast M, Mirsharifi A, Elyasfina F, Parsaei R, Kondori H, Farifteh S. Nicolau syndrome after intramuscular benzathine penicillin injection. Iran J Med Sci. 2014;39(6):577-9.

47. Bellot B, Bonnet C, Retornaz K, Panuel M, Garnier JM, Dubus JC, et al. [Nicolau syndrome after intramuscular injection]. Arch Pediatr. 2014;21(4):377-80. doi:10.1016/j.arcped.2014.01.016

48. Ergul Y, Soydemir D, Tastan Y, Omeroglu RE. Does early hyperbaric oxygen therapy prevent extremity necrosis in Nicolau syndrome? Pediatr Int. 2012;54(3):e15-8. doi:10.1111/j.1442-200X.2011.03475.x

49. Karimi M, Owlia MB. Nicolau syndrome following intramuscular penicillin injection. J Coll Physicians Surg Pak. 2012;22(1):41-2.

50. Ocaş S, Ekici B, Cam H, Tastan Y. Nicolau syndrome after intramuscular benzathine penicillin treatment. Pediatr Infect Dis J. 2006;25(8):749. doi:10.1097/01.inf.0000226941.85500.9b

51. Wroniec K, Czerneck J. [The Nicolau syndrome in children]. Eur J Pediatr Surg. 1981;32(4):367-70. doi:10.1055/s-2008-1063286

52. Ryan N, Olson A. Aseptic myonecrosis following intramuscular benzathine penicillin g injection: A novel syndrome. Diagnosis. (Berl) 2017;4(1):51-4. doi:10.1515/dx-2016-0040

53. Elfatooki FZ, Ennajdi A, Gueddari W, Chiheb S. [Nicolau livedoid dermatitis with severe neurological involvement in a child]. Ann Dermatol Venereol. 2017;144(6-7):426-9. doi:10.1016/j.annderm.2017.03.007

54. Quincer E, Jaggi P. Nicolau syndrome: A rare complication following intramuscular injection. J Pediatr. 2019;212:238-238.e2. doi:10.1016/j.jpeds.2019.04.004

55. Phiri W, Musonda MS, Kyakilika K, Miyoba MH, Malumani M. Nicolau syndrome following intramuscular benzathine penicillin injection: A case report. Pan Afr Med J. 2020;37:276. doi:10.11604/pamj.2020.37.276.21850

56. Raju B, Ashraf Q, Junam F, Appaji Gowda NM, Gupta G, Sun H, et al. Nicolau syndrome, masquerader of postinjection sciatic nerve injury: Case report and review of literature. World Neurosurg. 2020;143:51-5. doi:10.1016/j.wneu.2020.07.029

57. Demircan C, Akdogan N, Elmas L. Nicolau syndrome following intramuscular dexamphetamine injection: A case report and review of literature. J Clin Diagn Res. 2017;21(2):266-7. doi:10.1111/j.1468-0303.2006.01837.x

58. Mutalik S, Belgaumkar V. Nicolau syndrome: A report of 2 cases. J Drugs Dermatol. 2006;5(4):377-8.

59. Geerts JW, Siegel AM, Bosman A. [a woman with complaints after an injection of diclofenac]. Ned Tijdschr Geneeskd. 1995;39(8):1128-30. doi:10.1111/j.1399-6576.1995.tb04243.x

60. H. Nicolau syndrome. Arch Iran Med. 2017;20(1):60-2. doi:10.4103/aim.AIAN_298_18

61. Primum non nocere. Ann Indian Acad Neurol. 2019;22(1):104-8. doi:10.4103/aian.AIAN_298_18

62. Shelley BP, Prasad P, Manjunath MM, Chakraborti S. Hyperacute paraplegia and neurovascular (immuno vasculotoxic) catastrophe and nerve necrosis with intramuscular administration of diclofenac (voltaren). Acta Anaesthesiol Scand. 1995;39(8):1128-30. doi:10.1111/j.1399-6576.1995.tb04243.x

63. Killedar RS, Gupta S, Shindhe P. Ayurveda management of Nicolau syndrome w.S.R to kotha - a case report. J Ayurveda Integr Med. 2021;12(1):165-8. doi:10.1016/j.jaim.2020.07.004

64. Rygnestad T, Kvam AM. Streptocccal myositis and tissue necrosis with intramuscular administration of diclofenac (voltaren). Acta Anaesthesiol Scand. 1995;39(8):1128-30. doi:10.1111/j.1399-6576.1995.tb04243.x

65. Wronecki K, Czernik J. [The Nicolau syndrome in children]. Eur J Pediatr Surg. 1981;32(4):367-70. doi:10.1055/s-2008-1063286

66. Maneshi A, Ravi S, Salehi MR, Hasannezhad M, Khalili H. Nicolau syndrome. Arch Iran Med. 2017;20(1):60-4. doi:10.22031/AIM.0013

67. Memarian S, Gharib B, Gharagozloo M, Alimadadi H, Ahmadianejad Z, Ziaee V. Nicolau syndrome due to penicillin injection: A report of 3 cases without long-term complication. Case Rep Infect Dis. 2016;2016:9082158. doi:10.1155/2016/9082158

68. Rajadhyaksha G, Limaye C, Meah A, Gaikwad S, Jain S. Acute transverse myelitis and Nicolau syndrome after benzathine penicillin injection. J Assoc Physicians India. 2016;64(9):95-6.

69. Alkan Bozkaya T, Demirel G, Ormeci T, Al S, Cakar E, Tastekin A, et al. Anticoagulant and vasodilator therapy for Nicolau syndrome following intramuscular benzathine penicillin injection in a 4 year old boy. Arch Argent Pediatr. 2016;114(3):e184-6. doi:10.5546/aap.2016.0013

70. Memarian S, Gharib B, Gharagozloo M, Alimadadi H, Ahmadianejad Z, Ziaee V. Nicolau syndrome due to penicillin injection: A report of 3 cases without long-term complication. Case Rep Infect Dis. 2016;2016:9082158. doi:10.1155/2016/9082158

71. Rajadhyaksha G, Limaye C, Meah A, Gaikwad S, Jain S. Acute transverse myelitis and Nicolau syndrome after benzathine penicillin injection. J Assoc Physicians India. 2016;64(9):95-6.
syndrome secondary to subcutaneous glatiramer acetate injection. Int J Low Extrem Wounds. 2020. doi:10.1177/1534734620973144

58. Kimbrough DJ, Newsome SD. Case report: Two cases of nicolau syndrome associated with glatiramer acetate. Int J MS Care. 2017;19(3):148-50. doi:10.7224/1537-2073.2016-038

59. Benmiloud S, Hida M. [Nicolau syndrome complicating an intramuscular injection of benzathine penicillin]. Pan Afr Med J. 2014;18:105. doi:10.11604/panmj.2014.18.1056452

60. Andre P, Hanke E. Nicolau syndrome due to hyaluronic acid injections. J Cosmet Laser Ther. 2016;18(4):239-44. doi:10.3109/14764172.2016.1157260

61. Polychronis G-G, Stephanos K, Panayiotides. IG, Dimitriadis. GD, Konstantinos T. Embolia cutis medicamentos: An unusual adverse reaction to terlipressin. Ann Gastroenterol. 2017;30(6):700-3. doi:10.20534/aag.2017.0158

62. Ossorio-Garcia L, Jimenez-Gallo D, Arjona-Aguilera C, Linares-Barrios M. Multimodal treatment of calciphylaxis with sodium thiosulfate, alprostadil, and hyperbaric oxygen therapy. Actas Dermosifiliogr. 2016;107(8):695-7. doi:10.1016/j.ad.2016.04.004

63. Vlahova L, Kretschmer L, Schon MP, M ossner R. Embolia cutis medicamentos: secondary to subcutaneous injection with glatiramer acetate. Case Rep Dermatol. 2021;13(1):114-20. doi:10.1159/000510017

64. Begin P, Anne DR. Nicolau syndrome may be caused by intravascular vaccine injection. Vaccine. 2012;30(11):2035-6. doi:10.1016/j.vaccine.2011.10.107

65. Mueller P, Forner C, Kurze G. Embolia cutis medicamentosa (nicolau syndrome) due to vaccination. Dermatol. 1997;137(6):1030-1. doi:10.1111/j.1365-2133.1997.tb01585.x

66. Navrathina K, Cresseý BD, Wildman HF. Nicolau syndrome after lumbar puncture: A case report in a 22-month-old girl. JAAAD Case Rep. 2017;3(1):33-5. doi:10.1016/j.jdcr.2016.09.004

67. Lee DP, Baé GY, Lee MW, Choi JH, Moon KC, Koh JK. Nicolau syndrome caused by piroxicam. Int J Dermatol. 2005;44(12):1069-70. doi:10.1111/j.1365-4632.2004.02534.x

68. Grover C, Kharghoria G, Daulatabad D, Bhattacharya SN. Nicolau syndrome following intramuscular triamcinolone injection for nail lichen planus. Indian Dermatol Online J. 2017;8(5):350-1. doi:10.4103/idoj.IDOJ_333_16

69. Seremet S, Turan E, Erdemir AT. Nicolau syndrome following intramuscular injection of oxytocin in pregnant women: Report of two cases. Dermatol Online J 2015;15;21(8):13030/q8q81z5mh.

70. Zaragoza J, Delaplace M, Benamar M, Esteve E. [A rare side effect of mesotherapy: Nicolau syndrome], Ann Dermatol Venereol. 2013;140(11):713-7. doi:10.1016/j.annder.2013.07.009

71. Korkomaz J, Maatouk I, Moutran R, Helou J. Images in vascular medicine. Nicolau livedoid dermatitis occurring after sclerotherapy. Vasc Med. 2014;19(5):415-6. doi:10.1117/1358863X14537884

72. Bieveled M, Aldenznee M. [A young woman with skin necrosis after sclerotherapy]. Ned Tijdschr Geneeskd. 2015;159:A9074.

73. Rasokat H, Bendick C, Wemmer U, Steigleder GK. Aseptische hauernekrose nach subkutaner injektion von interferon-alpha. Dtsch Med Wochenschr. 1989;114:458-60.

74. Saylam Kurtipek G, Tunçez Akyürek F, Ataseven A. Nicolau syndrome after diclofenac-thiocolchicoside intramuscular injection. Eur J Gen Med. 2014;11(4):305-6. doi:10.15197/sabad.1.11.94

75. Guarnieri C, Polimeni G, Guarnieri F, Cuzzocrea S. Embolia cutis medicamentos following thiocolchicoside injection. J Eur Acad Dermatol Venereol. 2008;22(8):1005-6. doi:10.1111/j.1365-3083.2007.02527.x

76. Ozlu E, Baykan A, Ertas R, Ulas Y, Ozzyurt K, Avci A, et al. Case report: Nicolau syndrome due to etofenamate injection. F1000Res. 2017;6:867. doi:10.12688/f1000research.11705.1

77. Tabor D, Bertram CG, Williams AJK, Mathers ME, Biswas A. Nicolau syndrome (embolia cutis medicamentos): A rare and poorly recognized iatrogenic cause of cutaneous thrombotic vasculopathy. Am J Dermatopathol. 2018;40(3):212-5. doi:10.1097/ 1365-8632.2007.02527.x

78. Grover C, Kharghoria G, Daulatabad D, Bhattacharya SN. Nicolau syndrome following intramuscular triamcinolone injection for nail lichen planus. Indian Dermatol Online J. 2017;8(5):350-1. doi:10.4103/idoj.IDOJ_333_16

79. Greenky D, Dixon R. Adolescent with pain and necrosis following intramuscular injection. JAMA Pediatr. 2017;171(10):1008-9. doi:10.1001/jp.2017.0333

80. Espitia Q, Vigneau-Victorri C, Pistorius MA. Image gallery: Nicolau syndrome after misuse of buprenorphine. Br J Dermatol. 2017;176(4):e35. doi:10.1111/bjd.15322

81. Srivastava P, Someshwar S, Jerajani H. Nicolau's syndrome. Indian Pediatr. 2015;52(4):356.
injection. J Eur Acad Dermatol Venereol. 2014;30(2):348-50. doi:10.1111/jdv.12759
85. Nirmal B, Segu SS, Sacchidanand SA, Deshpande P. Nicolau syndrome following sclerotherapy for pyogenic granuloma. Indian J Dermatol Venereol Leprol. 2014;80(5):484. doi:10.4103/0378-6323.140356
86. McKinney C, Sharma N, Jerath RS. Livedoid dermatitis (nicolau syndrome) following intra-articular glucocorticoid injection. J Clin Rheumatol. 2014;20(6):339-40. doi:10.1097/RHU.0000000000000146
87. Kim DH, Ahn HH, Kye YC, Choi JE. Nicolau syndrome involving whole ipsilateral limb induced by intramuscular administration of gentamycin. Indian J Dermatol Venereol Leprol. 2014;80(1):96. doi:10.4103/0378-6323.125516
88. Guarneri C, Bevelacqua V, Polimeni G. Embolia cutis medicamentosa (nicolau syndrome). QJM. 2012;105(11):1127-8. doi:10.1093/qjm/2cr194
89. Wilbrand JF, Wilbrand M, Schaaf H, Howaldt HP, Malik CY, Streckbein P. Embolia cutis medicamentosa (nicolau syndrome) after endodontic treatment: A case report. J Endod. 2011;37(6):875-7. doi:10.1016/j.joen.2011.01.004
90. Garcia-Vilanova-Comas A, Fuster-Diana C, Cubells-Parrilla M, Perez-Ferriols MD, Perez-Valles A, Roig-Vila JV. Nicolau syndrome after lidocaine injection and cold application: A rare complication of breast core needle biopsy. Int J Dermatol. 2011;50(1):78-80. doi:10.1111/j.1365-4632.2009.04446.x
91. Guarneri C, Polimeni G. Nicolau syndrome following etanercept administration. Am J Clin Dermatol. 2010;11 Suppl 1:51-2. doi:10.2165/1153426-0000000000-00000
92. Koklu E, Sarici SU, Altun D, Erdeve O. Nicolau syndrome induced by intramuscular vitamin k in a premature newborn. Eur J Pediatr. 2009;168(12):1541-2. doi:10.1007/s00431-009-0964-6
93. Razinskas G, Lechner W. [Embolia cutis medicamentosa following intramuscular injection of pyrazolone-containing preparations]. Z Hautkr. 1985;60(20):1639-45.
94. Perli D, Martone C, Rapose A. Naltrexone-induced nicolau syndrome masquerading as cutaneous abscess. BMJ Case Rep. 2012;2012:bcr2012007785. doi:10.1136/bcr-2012-007785
95. Wang B, Zhou H, Lu G, Liu Q, Jiang X. Bifunctional oxo-tethered ruthenium complex catalyzed asymmetric transfer hydrogenation of aryl n-heteroaryl ketones. Org Lett. 2017;19(8):2094-7. doi:10.1021/acs.orglett.7b00691
96. Senel E. Nicolau syndrome as an avoidable complication. J Family Community Med. 2012;19(1):52-3. doi:10.4103/2230-8229.94017
97. Kartal SP, Alper M, Gurbay N. Nicolau syndrome: A rare complication of injection that should be kept in mind. Hong Kong J. 2016;24:201-4.
98. Gayken J, Westanno A, Knutsen A, Ahrenholz DH, Mohr III WJ, Solem LD. Livedoid dermatitis and severe necrosis (nicolau's syndrome) after intramuscular hydroxyazine injection. J Burn Care Res. 2006;27(4):541-4. doi:10.1097/01.BCR.0000225917.09339.03
99. Murthy SC, Siddalingappa K, Suresh T. Nicolau's syndrome following diclofenac administration: A report of two cases. Indian J Dermatol Venereol Leprol. 2007;37(6):429-31. doi:10.4103/0378-6323.37070
90. The international encyclopedia of adverse drug reactions and interactions. 16th ed. Amsterdam: Elsevier; 2015.
91. Yebenes M, Gilaber M, Toll A, Barranco C, Pujol RM. Localized retiform purpura after accidental intra-arterial injection of polidocanol. Acta Derm Venereol. 2005;85(4):372-3. doi:10.1080/000155505010027856
92. Miranda MCC, Rozenfeld S, Olivera SP. A systematic review of the nonallergic adverse reactions following benzathine penicillin injections. J Vasc Br. 2004;3:253-60.
93. Saputo V, Brunì G. [Nicolau syndrome caused by penicillin preparations: Review of the literature in search for potential risk factors]. Pediatr Med Chir. 1998;20(2):105-23.
94. Brachtel R, Meinerzt T. Local skin necroses after intramuscular injection -experimental animal studies. Arch Dermatol Res. 1977;258(3):281-8.
95. Silva AMM, Ton A, Loureiro TF, Agrizzi BL. Late development of nicolau syndrome: Case report. An Bras Dermatol. 2011;86(1):157-9. doi:10.1590/s0365-05962011000100026
96. McGee AM, Davison PM. Skin necrosis following injection of non-steroidal anti-inflammatory drug. Br J Anaesth 2002;88(1):139-40. doi:10.1093/bja/88.1.139
97. Kakati A, Bhat D, Devi BI, Shukla D. Injection nerve palsy. J Neurosci Rural Pract. 2013;4(1):13-8. doi:10.4103/0976-3147.105603
98. Zhuo P, Gao D, Xia Q, Ran D, Xia W. Sciatic nerve injury in children after gluteal intramuscular injection: Case reports on medical malpractice. Med Sci Law. 2019;59(3):139-42. doi:10.1177/0025802419851980
99. Kim KK, Chae D. Nicolau syndrome: A literature review. World J Dermatol. 2015;4:103-7. doi:10.5314/wjd.v4.i2.103
100. Sh J, Yp GC, J R. Iatrogenic non-clostridial gas gangrene - a case report. Med Leg J. 2016;84(1):49-51. doi:10.7326/0003-4819-84-1-49-51
101. Van Hook R, Vandevelde AG. Letter: Gas gangrene: A case report. Med Leg J. 2016;84(1):49-51. doi:10.7326/0003-4819-84-1-49-51
102. Anggadisakis J, Lasithiotakis K, Topalidou A, Koutroumpas J, Kouvidis G, Katonis P. Limb salvage after gas gangrene: A case report and review of the literature. World J Emerg Surg. 2011;6:28. doi:10.1186/1749-7922-6-28

Pharmaceutical Sciences, 2022, 28(1), 27-38 | 37
113. Uri O, Arad E. Skin necrosis after self-administered intramuscular diclofenac. J Plast Reconstr Aesthet Surg. 2010;63(1):e4-5. doi:10.1016/j.bjps.2009.01.049
114. Jung Kim H, Hyun Park S. Sciatic nerve injection injury. J Int Med Res. 2014;42(4):887-97. doi:10.1177/0300060514531924
115. Pullen RL, Jr. Administering medication by the z-track method. Nursing. 2005;35(7):24. doi:10.1097/00152193-200507000-00018